Monday, November 15, 2010

Medical News

Medical News


EP4 receptor feasible target for antithrombotic agents

Posted: 15 Nov 2010 04:00 PM PST

Austrian researchers have found that human platelets express the E-type prostaglandin receptor 4, which inhibits platelet aggregation when activated.

Unfavorable lipid profile associated with <i>APOE</i> isoform

Posted: 15 Nov 2010 04:00 PM PST

Research suggests that there are close associations between APOE genotypes and lipid profiles in the Brazilian population.

JUPITER data behind European approval released

Posted: 15 Nov 2010 04:00 PM PST

Post hoc analyses of JUPITER that formed the basis for European approval of rosuvastatin have been published in the European Heart Journal.

High intrinsic coagulation activation may increase arterial thrombosis risk

Posted: 14 Nov 2010 04:00 PM PST

High levels of activated intrinsic coagulation proteins are associated with an increased risk for arterial thrombosis in young women, study findings indicate.

FLAIR changes serve as clock for time since stroke onset

Posted: 14 Nov 2010 04:00 PM PST

Signal intensity changes on fluid-attenuated inversion recovery magnetic resonance imaging provide a sensitive indicator of time since stroke onset, report researchers.

Low prostate weight linked to PSMs in low-risk prostatectomy patients

Posted: 14 Nov 2010 04:00 PM PST

Men with low-risk prostate cancer are more likely to have positive surgical margins after treatment with nerve-sparing robotic-assisted radical prostatectomy if they have a light rather than heavy prostate, researchers report.

Lasofoxifene is attractive option for breast cancer prevention

Posted: 14 Nov 2010 04:00 PM PST

The selective estrogen-receptor modulator lasofoxifene appears to reduce the risks for both total, and ER-positive invasive breast cancer in postmenopausal women with osteoporosis, the results of a randomized-controlled trial show.

Prostate cancer becomes more aggressive with age, could impact screening

Posted: 14 Nov 2010 04:00 PM PST

Study findings show that as men with prostate cancer age, more aggressive disease characteristics emerge, lessening their chances of survival compared with younger men with the disease.

CV benefits of fish oil may have been overestimated

Posted: 14 Nov 2010 04:00 PM PST

German researchers say that the benefits of omega-3 fatty acids in survivors of acute myocardial infarction, beyond those achieved with modern guideline-adjusted therapy, may have been overestimated.

Apolipoproteins mediate Lp-PLA<sub>2</sub>–CVD link

Posted: 14 Nov 2010 04:00 PM PST

Associations between circulating levels of lipoprotein-associated phospholipase A2 and cardiovascular diseases are dependent on pro-atherogenic lipid levels, research shows.

Eplerenone boosts survival in mild systolic heart failure patients

Posted: 14 Nov 2010 04:00 PM PST

Eplerenone, in addition to recommended therapy, significantly reduces cardiovascular death and hospitalization for heart failure in patients with systolic heart failure and mild symptoms, results from EMPHASIS-HF indicate.

HeartWare® ventricular assist system meets non-inferiority goal

Posted: 14 Nov 2010 04:00 PM PST

Success rates with HeartWare®, a continuous-flow left ventricular assist device for the treatment of patients with advanced heart failure, are comparable to those of commercially available devices, findings from the ADVANCE trial show.

Telemedicine may reduce diabetics’ food insecurities

Posted: 14 Nov 2010 04:00 PM PST

Low-income diabetics who live in rural areas and have concerns about sufficient food availability can still adhere to a diabetes-appropriate diet if given nutritional counseling using telemedicine, a US study suggests.

HbA1C measurements misleading during iron, erythropoietin therapy

Posted: 14 Nov 2010 04:00 PM PST

UK researchers report that glycated hemoglobin levels do not accurately reflect the glycemic control of diabetic patients who receive intravenous iron and erythropoietin-stimulating agents for co-existing chronic kidney disease.

Eplerenone boosts survival in mild systolic heart failure patients

Posted: 14 Nov 2010 04:00 PM PST

Eplerenone, in addition to recommended therapy, significantly reduces cardiovascular death and hospitalization for heart failure in patients with systolic heart failure and mild symptoms, results from EMPHASIS-HF indicate.

HeartWare® ventricular assist system meets non-inferiority goal

Posted: 14 Nov 2010 04:00 PM PST

Success rates with HeartWare®, a continuous-flow left ventricular assist device for the treatment of patients with advanced heart failure, are comparable to those of commercially available devices, findings from the ADVANCE trial show.

No comments:

Post a Comment